Full Press Release Details
Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of
its Oral Insulin Capsule
Israel - May 5, 2009 - Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB; www.oramed.com),
a developer of oral delivery systems, announced that Phase 2b clinical trials
will commence this week on 30 Type 2 Diabetic volunteers. The study is intended
to evaluate the safety, tolerability and efficacy of its oral insulin capsule
ORMD-0801. OnQ Consulting, a clinical research organization (CRO) located in
Johannesburg, South Africa, will oversee the clinical trials. This
trial is an important milestone for Oramed as it will test its first indication
for ORMD-0801 on a large group of volunteers for the duration of six
week randomized, double blind placebo controlled study will be performed in
three locations in Cape Town. The principle investigators of the study will be
renowned South African Endocrinologists.
pleased to begin this study of ORMD-0801 on Type 2 diabetes patients following
our successful 2A clinical trials in August 2008. This trial is an
important milestone for Oramed as this is the first trial for ORMD-0801 on a
larger group of volunteers for a longer duration." said Oramed's CEO, Mr. Nadav
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit www.oramed.com
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts: